SCOL.ST
Price:
$0.0041
Market Cap:
$660.19K
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company's other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors. Scandion Oncology A/S was founded in 2017 and is headquartered in Copenhagen, Denmark.
Industry
Biotechnology
IPO Date
2018-11-08
Stock Exchange
STO
Ticker
SCOL.ST
According to Scandion Oncology A/S’s latest financial reports and current stock price. The company's current PE Ratio is -0.02. This represents a change of -98.49% compared to the average of -1.13 of the last 4 quarters.
The mean historical PE Ratio of Scandion Oncology A/S over the last ten years is -10.39. The current -0.02 PE Ratio has changed -83.55% with respect to the historical average. Over the past ten years (40 quarters), SCOL.ST's PE Ratio was at its highest in in the December 2024 quarter at -0.19. The PE Ratio was at its lowest in in the December 2019 quarter at -340.63.
Average
-10.39
Median
-5.37
Minimum
-30.64
Maximum
0
Discovering the peaks and valleys of Scandion Oncology A/S PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 226.56%
Maximum Annual PE Ratio = 0
Minimum Annual Increase = -100.00%
Minimum Annual PE Ratio = -30.64
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | 0 | -100.00% |
| 2023 | -2.77 | 166.78% |
| 2022 | -1.04 | -81.28% |
| 2021 | -5.55 | -80.84% |
| 2020 | -29.00 | 226.56% |
| 2019 | -8.88 | 70.95% |
| 2018 | -5.19 | -83.05% |
The current PE Ratio of Scandion Oncology A/S (SCOL.ST) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.27
5-year avg
-7.67
10-year avg
-10.39
Scandion Oncology A/S’s PE Ratio is greater than ExpreS2ion Biotech Holding AB (publ) (-0.92), greater than Hansa Biopharma AB (publ) (-4.75), greater than FluoGuide A/S (-9.86), less than Saniona AB (publ) (13.45), greater than Oncopeptides AB (publ) (-4.35),
| Company | PE Ratio | Market cap |
|---|---|---|
| -0.92 | $42.05M | |
| -4.75 | $3.04B | |
| -9.86 | $505.31M | |
| 13.45 | $3.02B | |
| -4.35 | $1.11B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Scandion Oncology A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Scandion Oncology A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Scandion Oncology A/S's PE Ratio?
How is the PE Ratio calculated for Scandion Oncology A/S (SCOL.ST)?
What is the highest PE Ratio for Scandion Oncology A/S (SCOL.ST)?
What is the 3-year average PE Ratio for Scandion Oncology A/S (SCOL.ST)?
What is the 5-year average PE Ratio for Scandion Oncology A/S (SCOL.ST)?
How does the current PE Ratio for Scandion Oncology A/S (SCOL.ST) compare to its historical average?